STAT1 and hepatocellular carcinoma: Considering the tumor-suppressive effects of pravastatin in preclinical animal models of HCC [168], the STAT1 inhibitor was assessed for its anticancer effects in clinical studies (NCT01418729, NCT01903694, and NCT01075555).